Gainers
-
Stellar Biotechnologies, Inc. (NASDAQ: SBOT) rose
32 percent to $2.89 in pre-market trading after the company disclosed that it achieved robust viral clearance for its
manufacturing process.
-
Babcock & Wilcox Enterprises, Inc. (NYSE: BW) rose
17.7 percent to $3.03 in pre-market trading after an amended 13D filing from Steel Partners Holdings shows a raised stake in
the company from 6.99 million shares to 29.98 million shares, or a 17.8 percent stake.
-
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)
shares rose 12.7 percent to $3.55 in pre-market trading after the company announced the FDA acceptance of NDA for DSUVIA.
-
Williams-Sonoma, Inc. (NYSE: WSM) shares rose 11.7
percent to $54.95 in pre-market trading. after the company reported stronger-than-expected results for its first quarter. The
company also raised its FY18 earnings and sales guidance.
-
Bilibili Inc. (NASDAQ: BILI) shares rose 9.3
percent to $13.59 in pre-market trading after announcing Q1 results.
-
Stein Mart, Inc. (NASDAQ: SMRT) rose 8.1 percent
to $3.46 in pre-market trading after reporting strong Q1 earnings.
-
Universal Corporation (NYSE: UVV) rose 8.1 percent
to $52.35 in pre-market trading after reporting fiscal Q4 results.
-
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) rose
8.1 percent to $5.65 in pre-market trading after gaining 6.30 percent on Wednesday.
-
CEL-SCI Corporation (NYSE: CVM) rose 6.1 percent to
$3.30 in pre-market trading after climbing 9.51 percent on Wednesday.
-
TransEnterix, Inc. (NYSE: TRXC) rose 6 percent to
$3.10 in pre-market trading after reporting a loan deal for $40 million in term loans with Hercules Capital.
-
Stage Stores, Inc. (NYSE: SSI) rose 5.6 percent to
$3.40 in pre-market trading following Q1 results.
-
Koss Corporation (NASDAQ: KOSS) shares rose 5.2
percent to $2.42 in the pre-market trading session after falling 2.54 percent on Wednesday.
Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.
Check out these big penny stock gainers and
losers
Losers
-
Recro Pharma, Inc. (NASDAQ: REPH) fell 50.3
percent to $6.17 in pre-market trading after the company received a Complete Response Letter from the FDA. The FDA declined to
approve the company’s New Drug Application for IV meloxicam.
-
Westell Technologies, Inc. (NASDAQ: WSTL) shares
fell 16.5 percent to $2.89 in pre-market trading after the company announced Q4 results.
-
Melinta Therapeutics, Inc. (NASDAQ: MLNT) fell
16.5 percent to $5.20 in pre-market trading after reporting pricing of public offering of common stock.
-
Westmoreland Resource Partners, LP (NYSE: WMLP)
fell 11 percent to $3.49 in pre-market trading after surging 194.03 percent on Wednesday.
-
Petróleo Brasileiro S.A. - Petrobras (NYSE: PBR)
shares fell 11 percent to $13.45 in pre-market trading. Petrobras announced plans to lower the cost of diesel by 10 percent.
-
Sanderson Farms, Inc. (NASDAQ: SAFM) shares fell
9.4 percent to $97 in pre-market trading after the company reported weaker-than-expected results for its second quarter.
-
Zealand Pharma A/S (NASDAQ: ZEAL) fell 6.9
percent to $15.55 in pre-market trading after rising 2.71 percent on Wednesday.
-
L Brands, Inc. (NYSE: LB) shares fell 6.7 percent to
$31.76 in pre-market trading after the company reported weaker-than-expected earnings for its first quarter. The company issued
weak second quarter and FY18 earnings guidance.
-
ReTo Eco-Solutions, Inc. (NASDAQ: RETO) shares
fell 5.9 percent to $4.78 in pre-market trading.
-
Qiwi plc (NASDAQ: QIWI) fell 5.9 percent to
$17.52 in pre-market trading.
-
Eiger Biopharmaceuticals Inc (NASDAQ: EIGR) fell
5 percent to $13.25 in pre-market trading after reporting a proposed offering of common stock.
-
Best Buy Co Inc (NYSE: BBY) shares fell 4.3 percent
to $72.66 in pre-market trading. Best Buy reported better-than-expected earnings for its first quarter.
-
NetApp Inc. (NASDAQ: NTAP) fell 4.1 percent to
$64.08 in pre-market trading despite reporting a fourth-quarter earnings beat. The company sees FY19 sales growth in the
mid-single digits.
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.